Fritextsökning
Artiklar per år
Innehållstyper
-
Actives cancerpreparat studeras
Nu kommer resultaten från två parallella studier av preparatet Anyara.
-
Patientrekrytering klar för Active
I sitt samarbete med Teva Pharmaceutical Industries har Active Biotech nu avslutat patientrekryteringen till en fas III-studie.
-
Actives nyemission övertecknad
Den 30 juni är sista dag för handel med betalda tecknade aktier.
-
Viktigt steg för Active i nya fas II-studien
Patientrekryteringen är nu färdig för Active Biotechs nya cancerpreparat.
-
Actives patientrekrytering för fas III-studie klar
Active Biotech har nu avslutat patientrekryteringen till studien av Anyara.
-
Ny ledamot till Active Biotech
Vid Actives årsmöte valdes Tomas Nicolin in till ny ledamot i styrelsen.
-
Active Biotech tar in nya pengar
Active genomför en nyemission i maj. På läkemedelsföretagets årsmöte fick styrelsen också ägarnas mandat att besluta om en till emission under året som kommer.
-
Active Biotech får gräddfil
Den amerikanska läkemedelsmyndigheten, FDA, har beviljat Fast Track-status för ett av det svenska bolagets läkemedel.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Harmony prevents dementia
People who are active, outgoing and relaxed may be less likely to develop dementia, according to a new study from Karolinska Institutet.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Vitrolife wants to acquire Medicult
The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Norwegian describes scrapie gene
Intestinal lymphatic tissue is important for the absorption and spread of the scrapie prion, suggests a Norwegian researcher.
-
Recipharm launches into biologics manufacturing
Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.
BREAKING